Astra-Oxford shot is key to escaping pandemic

TheStar Mon, Nov 23, 2020 09:40am - 3 years View Original


Findings from the final stage of AstraZeneca Plc’s vaccine studies are due to be released shortly, and the stakes for lower- and middle-income nations are immense. The shot developed with the University of Oxford accounts for more than 40% of the supplies going to those countries, based on deals tracked by London-based research firm Airfinity Ltd.

LONDON: Trial successes from Pfizer Inc and Moderna Inc have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of rich nations like the United States, is counting on another company’s shot to escape the crisis.

Findings from the final stage of AstraZeneca Plc’s vaccine studies are due to be released shortly, and the stakes for lower- and middle-income nations are immense. The shot developed with the University of Oxford accounts for more than 40% of the supplies going to those countries, based on deals tracked by London-based research firm Airfinity Ltd.

The Astra vaccine costs a fraction of the price set by Pfizer and will be manufactured in multiple countries, from India to Brazil. It should be easier to deploy far and wide than other shots that need to be stored at ultra-cold temperatures. But if the UK partners can’t match the lofty efficacy levels Pfizer and Moderna delivered or roll out their inoculation quickly, the pandemic might continue spreading death and disease in countries relying on it.

...

Full Article on TheStar

The content is a snapshot from Publisher. Refer to the original content for accurate info. Contact us for any changes.






Related Stocks

ASTRA 0.370

Comments

Login to comment.